Earnings Summary

Apogee Therapeutics’s revenue jumped NaN% since last year same period to $0Mn in the Q2 2024. On a quarterly growth basis, Apogee Therapeutics has generated NaN% jump in its revenue since last 3-months.

Apogee Therapeutics’s net profit fell -79.06% since last year same period to $-33.82Mn in the Q2 2024. On a quarterly growth basis, Apogee Therapeutics has generated -5.37% fall in its net profits since last 3-months.

Apogee Therapeutics’s net profit margin jumped NaN% since last year same period to -Inf% in the Q2 2024. On a quarterly growth basis, Apogee Therapeutics has generated NaN% jump in its net profit margins since last 3-months.

Apogee Therapeutics’s earning per share (EPS) estimates for the current quarter stand at -0.6 - a 1.64% jump from last quarter’s estimates.

Apogee Therapeutics’s earning per share (EPS) estimates for the current year stand at -0.6.

Apogee Therapeutics’s earning per share (EPS) jumped 84.13% since last year same period to -0.6 in the Q2 2024. This indicates that the Apogee Therapeutics has generated 84.13% annual rate of jump in its earning per share (EPS) in the last 4 quarters.

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Apogee Therapeutics’s return on assets (ROA) stands at -0.19.

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Apogee Therapeutics’s return on equity (ROE) stands at -0.27.